QRA-244 is under clinical development by QurAlis and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral Sclerosis have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QRA-244’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
QRA-244 is under development for the treatment of amyotrophic lateral sclerosis. They act by targeting voltage-gated potassium channel subunits Kv7.2 and Kv7.3. The drug candidates are developed based on stem cell technology platform and the Q-State optopatch platform. It is administered through oral route.
QurAlis carries out the business of discovering, developing and commercializing new therapies for the treatment of motor neuron disease such as amyotrophic lateral sclerosis (ALS). Its therapeutic programs include excitotoxicity in the motor system and restoration of autophagy pathways. It is also expanding its pipeline to other neurodegenerative diseases, such as frontotemporal-degeneration (FTD). QurAlis is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of QRA-244’s drug-specific PTSR and LoA scores, buy the report here.